Abstract:Abstract Background: The peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α) and Nuclear factor erythroid 2-related factor 2 (Nrf2) are key regulators controlling antioxidant defense, mitochondrial biogenesis and cellular proteostasis. Dysfunction of these processes has been implicated in the pathogenesis of Parkinson’s disease (PD). Activation of PGC-1α/Nrf2 might improve mitochondrial dysfunction, promote α-synuclein (α-syn) clearance and attenuate degeneration of nigral dopaminergic neurons in PD. Methods: Neurotoxin-induced in vitro PD model, 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated mice model, unilateral intrastriatal injection of 6-hydroxydopamine (6-OHDA)-lesioned rat model, and transgenic mice overexpression of human A53T mutant α-synuclein were used to evaluate the neuroprotective and neurorescue effect of tetramethylpyrazine nitrone (TBN), a free radical scavenger, and its regulation on PGC-1α/Nrf2 pathway. Results: TBN protected against 1-methyl-4-phenylpyridinium (MPP + ) and 6-OHDA insult in cultured primary midbrain neurons. TBN promoted α-syn clearance by autophagy and proteasomal pathways in cell models overexpressing the human A53T mutant α-syn. In MPTP-treated mice, unilateral 6-OHDA-lesioned rats, and the α-syn transgenic mice model, TBN improved motor impairment, increased survival of nigral dopaminergic neurons, and elevated striatal dopamine levels while decreasing the products of oxidative damage. Importantly, TBN down-regulated the α-syn level in the brain and serum of α-syn-transgenic mice. These in vitro and in vivo improvements were associated with activation of the PGC-1α/Nrf2 signaling pathway, resulting in reduced oxidative stress, and enhanced mitochondrial functions. Conclusions: Our work demonstrates that TBN activates PGC-1α/Nrf2 and increases the survival of nigral dopaminergic neurons. These results suggest that TBN warrants further development as a potential new PD treatment.

Thrombomodulin reduces α-synuclein generation and ameliorates neuropathology in a mouse model of Parkinson's disease

Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson's disease

MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease

Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration in Parkinson’s disease mouse model

Thioredoxin-1 decreases alpha-synuclein induced by MPTP through promoting autophagy-lysosome pathway

TMEM106B Knockdown Exhibits a Neuroprotective Effect in Parkinson's Disease via Decreasing Inflammation and Iron Deposition

α‐synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson’s disease

Minocycline inhibition of microglial rescues nigrostriatal dopaminergic neurodegeneration caused by mutant alpha-synuclein overexpression

Thiocyanate Reduces Motor Impairment in the hMPO-A53T PD Mouse Model while Reducing MPO-Oxidation of Alpha Synuclein in Enlarged LYVE1/AQP4 Positive Periventricular Glymphatic Vessels

Tetramethylpyrazine Nitrone Promotes the Clearance of Alpha-Synuclein via Nrf2-Mediated Ubiquitin–Proteasome System Activation

Tetramethylpyrazine nitrone exerts neuroprotection via PGC-1α/Nrf2 activation and α-synuclein clearance in Parkinson’s disease models

Peripherally administered TNF inhibitor is not protective against α-synuclein-induced dopaminergic neuronal death in rats

Tau knockout exacerbates degeneration of parvalbumin‐positive neurons in substantia nigra pars reticulata in Parkinson's disease‐related α‐synuclein A53T mice

Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in α-Synuclein-Based Mouse Models of Parkinson's Disease.

Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein

Curcumin Ameliorates the Neurodegenerative Pathology in A53T α-synuclein Cell Model of Parkinson’s Disease Through the Downregulation of mTOR/p70S6K Signaling and the Recovery of Macroautophagy

The PM20D1-NADA pathway protects against Parkinson's disease

Antioxidant Nanoparticles for Concerted Inhibition of α-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation

α-Mangostin Inhibits α-Synuclein-Induced Microglial Neuroinflammation and Neurotoxicity

Suppression of Abnormal Α-Synuclein Expression by Activation of BDNF Transcription Ameliorates Parkinson's Disease-Like Pathology.

In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation